Redmile Group, LLC

September 25, 2026

ATTO shares dip as investors question valuation after cancer vaccine news. Attovia Therapeutics' stock moved lower as investors raised concerns about whether its current valuation is justified. The scrutiny comes as the broader oncology space sees attention, highlighted by recent discussion of Moderna's cancer vaccine development. The stock is trading near the lower end of its 52‑week range, with RSI indicating modest momentum.

September 30, 2026

Atara Biotherapeutics Resubmits Tabelecleucel BLA to FDA. Atara Biotherapeutics and its partner Pierre Fabre have filed a new biologics license application for the Tabelecleucel therapy with the U.S. FDA. The resubmission follows the earlier filing and reflects the companies' effort to move the product toward approval. The stock is currently near a long‑standing support level, which may be watched as the regulatory process continues.

September 27, 2026

Fate Therapeutics Secures $15M CIRM Grant for Lupus Trial. Fate Therapeutics announced it received a $15 million grant from the California Institute for Regenerative Medicine to advance its Phase 2 RECLAIM-LN trial for lupus nephritis. This funding supports the development of the company's FT819 therapy. The news coincides with the stock trading near its 52-week low, providing a potential catalyst for the healthcare sector.

October 8, 2026

ADC Therapeutics Announces $86.6M Financing and Loan Amendments. ADC Therapeutics has secured $86.6 million through a private placement of 12.9 million shares at $1.42 each, along with warrants for 48.1 million shares. The company also amended its existing loan and royalty agreements. This capital raise provides additional liquidity to support operations, occurring while the stock trades near the top of its recent range.

October 16, 2026

UBS initiates coverage on Shattuck Labs with $17 price target. UBS has started covering Shattuck Labs, assigning a price target of $17. This new analyst view comes as the company prepares to present research at UEG Week 2026. The stock is currently trading near its 52-week low, making this fresh institutional attention a notable development for the company.

October 14, 2026

ABSI to Report Q3 2026 Results on Nov 12, Shares Drop. Absci will announce its third‑quarter 2026 financials on Nov. 12. The company’s shares fell after a recent analyst note that the stock trades near the lower end of its 52‑week range and a new price target of $14.50. The drop follows a whale‑level buying alert and a broader market move higher for several large names. The upcoming earnings release may clarify the company’s outlook.

October 13, 2026

ZYME News Highlights Potential Undervaluation and Raised Price Target. Recent coverage notes that Zymeworks may be about 39% undervalued based on its 2026 revenue guidance and the recent appointment of a chief investment officer. Truist Securities also kept its rating and lifted its price target to $34, reflecting continued confidence in the company's outlook.

September 27, 2026

TRDA sees institutional interest from NVIDIA and Merck. The Benzinga report notes that institutional investors linked to NVIDIA and Merck have increased their positions in TRDA. This activity signals growing confidence in the company’s pipeline and may attract additional attention from other investors. The move comes as TRDA trades near the lower end of its 52‑week range, providing a potential entry point for those monitoring the stock.